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ABSTRACT: During the last few years, next-generation se-
quencing (NGS) technologies have accelerated the detec-
tion of genetic variants resulting in the rapid discovery of
new disease-associated genes. However, the wealth of vari-
ation data made available by NGS alone is not sufficient
to understand the mechanisms underlying disease patho-
genesis and manifestation. Multidisciplinary approaches
combining sequence and clinical data with prior biologi-
cal knowledge are needed to unravel the role of genetic
variants in human health and disease. In this context, it
is crucial that these data are linked, organized, and made
readily available through reliable online resources. The
Swiss-Prot section of the Universal Protein Knowledge-
base (UniProtKB/Swiss-Prot) provides the scientific com-
munity with a collection of information on protein func-
tions, interactions, biological pathways, as well as human
genetic diseases and variants, all manually reviewed by
experts. In this article, we present an overview of the in-
formation content of UniProtKB/Swiss-Prot to show how
this knowledgebase can support researchers in the eluci-
dation of the mechanisms leading from a molecular defect
to a disease phenotype.
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Introduction
During the past decade, the widespread application of next-
generation sequencing technologies [Shendure and Ji, 2008] to the
study of human populations has accelerated the rate of identifica-
tion of human genetic variants [1000 Genomes Project Consortium
et al., 2012; Tennessen et al., 2012], although establishing causal rela-
tionships between variants and disease phenotypes remains a major
challenge. Multidisciplinary approaches that combine patient ge-
nomic sequence and clinical data with prior biological knowledge
[Davies et al., 2012] are one means to fully elucidate disease mecha-
nisms and establish the contribution of individual genetic variations
to the development and progression of human diseases [Barabási
et al., 2011; Furlong, 2013]. Although disease mutations could in
principle occur in any functional region of the genome, most re-
cent studies have utilized exome sequencing technologies to identify
those affecting protein-coding regions (see, for instance, the NHLBI
exome sequencing project at http://evs.gs.washington.edu/EVS/). In
this context, high-quality resources linking genetic and medical in-
formation to protein sequences and associated biological knowl-
edge, such as the manually curated section of the Universal Protein
Knowledgebase (UniProtKB/Swiss-Prot), may be extremely valu-
able. UniProtKB/Swiss-Prot provides the scientific community with
a collection of functional information on proteins, with accurate,
consistent, and rich annotations, all manually reviewed by experts.
Each UniProtKB/Swiss-Prot entry contains not only manually an-
notated protein sequence(s) encoded by one gene, but also expert
curated functional annotations, mostly gathered from the scientific
literature.
A complete, expertly curated human proteome was first made
publicly available in UniProtKB/Swiss-Prot in September 2008. By
“complete”, we mean that at least one representative protein se-
quence has been reviewed and annotated by an expert curator for
each protein-coding gene. This complete human proteome has since
been continuously reviewed and updated at each release, and cur-
rently consists of approximately 20,300 entries, representing a total
of some 40,000 sequences (including alternative splicing isoforms).
The process of expert manual curation includes a thorough re-
view of available information on sequence variants (mostly single
amino acid polymorphisms (SAPs)), and associated genetic dis-
ease information, as well as the normal protein function. Close to
70,000 SAPs are currently reported in UniProtKB/Swiss-Prot, 35%
of which are associated with one of over 4,000 described genetic dis-
eases. UniProtKB/Swiss-Prot stores information on variants along
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with functional data, structural information, protein–protein in-
teraction data, pathways, and phenotypic descriptions. This global
view can help users infer or establish relationships between variants
and disease phenotypes.
The aim of this article is to show users how to best exploit the
knowledge on protein function and sequence variation provided
by UniProtKB/Swiss-Prot for the generation of new hypotheses de-
scribing the mechanisms underlying genetic diseases.
Sequences and Variations
Variant annotation in UniProtKB/Swiss-Prot is the result of criti-
cal reading of relevant articles combined with an in-depth sequence
analysis. In order to provide a reliable set of protein variants, the first
step is to provide a correct sequence that could serve as a reference for
subsequent variant description. This process involves the creation
of a “canonical” sequence, which is displayed by default in the entry.
Our policy is to have the canonical sequence matching the trans-
lation of the reference genome. This sequence is often the longest
available, since this allows the description of the largest amount
of features. Any discrepancy between the canonical sequence and
others reported either in the literature, or in submissions to the In-
ternational Nucleotide Sequence Database Collaboration (INSDC,
i.e. DDBJ, ENA, and GenBank), is thoroughly reported in “Sequence
annotation (Features)” in the appropriate subsection. These differ-
ences may be biologically relevant, such as alternative promoter
usage, alternative splicing, alternative translation initiation, genetic
variants, RNA editing, or technical artifacts, such as sequencing
errors. To discriminate between these alternatives, sequences are
thoroughly studied; this involves the analysis of the gene structure,
a comparison with orthologous sequences and available Expressed
Sequence Tags (ESTs), as well as searches for published experimental
data. Alternative splicing isoforms are reported in such a way that at
least one isoform (canonical or alternative) described in the entry
matches a consensus CDS (http://www.ncbi.nlm.nih.gov/CCDS/).
Genetic variants stored in UniProtKB/Swiss-Prot correspond to mis-
sense changes and small insertion–deletions (indels) that have either
been reported in peer-reviewed publications, or are supported by
several cDNAs and submitted to dbSNP, a database that catalogs
short variations in nucleotide sequences. Mutations that truncate
or grossly alter the protein sequence (such as frameshifts and non-
sense mutations) are not currently annotated, but will be annotated
in the near future.
The Process of Expert Variant Curation
Expert curation is a costly and time-consuming endeavor. At
UniProtKB, we focus our curation efforts on gathering informa-
tion from peer-reviewed literature that deals with disease-associated
mutations with an impact on protein function. Neutral polymor-
phisms and variants of unknown pathological significance (VUS),
i.e. whose association with disease or disease risk is unknown, can
also be reported. The curation process (Fig. 1) starts with the se-
lection of relevant publications that describe the identification of
new variant(s) and/or novel gene–disease associations, the func-
tional characterization of new or existing variants, or that pro-
vide new information on protein function. A text-mining tool has
been developed to improve this process [Veuthey et al., 2014, sub-
mitted]. Users can also contact us to draw our attention to par-
ticularly interesting publications that are missing in the knowl-
edgebase. Once a publication has been selected for annotation, the
whole text is critically read and pertinent information is reported in
UniProtKB/Swiss-Prot as described elsewhere [Poux et al., 2014]. All
genetic variants to be curated, be it neutral polymorphisms, disease-
associated mutations, or unclassified variants, are controlled with
the Mutation Analyzer (Mutalyzer) sequence variation nomencla-
ture checker [Wildeman et al., 2008], using the reference sequence
cited by the authors. If the variant is correctly designated and the
variant description at nucleotide level is consistent with the pro-
posed change at protein level, it is integrated into UniProtKB/Swiss-
Prot in “Sequence annotation (Features)”, “Natural variant” (Fig. 2).
However, this position in UniProtKB/Swiss-Prot may not be iden-
tical to that published, since the position depends upon the
reference sequence used. The canonical sequence that serves as
reference may differ from the published reference sequence, for
example, they can be different alternative splicing isoforms. There
may be other reasons for discrepancies between published positions
and UniProtKB/Swiss-Prot. Some classical numbering systems may
be a legacy from the past. For instance, the numbering of colla-
gen alpha-1(I) chain (COL1A1) (UniProtKB/Swiss-Prot accession
P02452) variants traditionally starts at the beginning of the triple-
helical region at position 179 (when position 1 corresponds to the
initiator methionine), variants located in the N-terminus are simply
ignored. In UniProtKB/Swiss-Prot, COL1A1 variants, as well as all
other sequence features, are always numbered based on the canon-
ical sequence, starting at the initiator methionine. Each annotated
variant is given a unique and stable identifier (FTId) to allow the
implementation of reciprocal links with variation records in other
databases and also to facilitate citations in publications. If the variant
is reported in dbSNP, a link is provided.
If a variant is associated with one or more diseases, the acronym
of the disease(s) is indicated in the description field in “Sequence
annotation (Features)” (Fig. 2). Disease phenotypes are described
in “General annotation (Comments)” section, “Involvement in dis-
ease” (see below). The descriptions are concise and cover only the
main phenotypic features. They first indicate the name of the dis-
ease, followed by its acronym, and, if available, a link to the OMIM
database (http://www.omim.org/). Users can follow this link to get
additional information. After the disease description, a note, writ-
ten in controlled vocabulary, indicates the relationship between the
gene product and the disease, whether it be disease causing, disease
modifying, or altering the susceptibility to disease.
UniProtKB/Swiss-Prot Variant Pages
The variant-specific annotations can be visualized in the
UniProtKB/Swiss-Prot variant web pages [Yip et al., 2004]. These
pages can be accessed directly from the description field in “Sequence
annotation (Features)”. They contain the description of a defined
variant, the physicochemical properties of the original residue and
that of the missense, the BLOSUM score for the amino acid change,
the conservation of the residue across various species, the regions,
domains, or sites annotated in its vicinity (Fig. 3). The potential
association with a disease and the description of the phenotype are
also reported, as well as the bibliographic reference(s) dealing with
the variant.
On the Importance of Linking Variation Data to
Functional Characterization Data
In the last few years, it has become evident that genotype–
phenotype relationships are not straightforward [Cooper et al.,
2013]. As shown by recent studies [Das et al., 2014; Kenna et al., 2013;
Piton et al., 2013], variants originally reported as disease-associated
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Figure 1. Flowchart of variant annotation in UniProtKB/Swiss-Prot. Variant annotation is based on published experimental data. The first step
is to select a relevant article. This is achieved using several complementary approaches, including browsing specialized journals, alerts from
literature databases and text mining. Users are also invited to take part in this process by contacting us to draw our attention on obsolete entries
and/or to interesting publications. Articles linking protein information with medical disorders are critically reviewed by expert curators, and variant
identification, disease description, and/or protein functional characterization are annotated based on supporting evidence. This annotation is
submitted to various manual and automated checks before final integration into UniProtKB/Swiss-Prot. The disease nomenclature is based on
OMIM, if available. If the disorder is not reported in OMIM, names and acronyms are created by the UniProtKB/Swiss-Prot staff on the basis of
published reports.
may need to be reclassified as benign polymorphisms, and vice versa,
variants thought to be neutral polymorphisms may be reassessed as
contributors to disease when more sequencing and genotyping data
of both disease and apparently healthy populations become avail-
able. Variant classification is an error-prone exercise whose result
depends on the amount and quality of available data. An efficient
approach to the understanding of the pathological relevance of ge-
netic variants should take into account experimental evidences of
variant effect on protein properties, as a complement to statisti-
cal genetics considerations and computational methods predicting
missense variants deleteriousness. Thanks to rich and accurate an-
notations, variant data in UniProtKB/Swiss-Prot are embedded in
the biochemical context defining protein properties and activities.
Whenever variant characterization data are available in the litera-
ture, it is reported in the description field in “Sequence annotation
(Features)”, “Natural variant” (Fig. 2), in free text form. Currently,
about 6,200 variants in UniProtKB/Swiss-Prot are associated with
some curated characterization data, and this number is continuously
increasing. We are also working on improving the representation of
this information by combining existing ontologies such as the Vari-
ation Ontology (VariO) (http://www.variationontology.org), which
describes variants and their effects [Vihinen, 2014], and the Gene
Ontology (GO), which describes the characteristics of normal pro-
teins (and which is already used routinely in UniProtKB). A com-
bination of terms from the two ontologies is used to specify the
characteristic of a normal protein (GO) and the effect of a given
variant on it (VariO).
To further facilitate data access and utilization, a new interface
that provides powerful SPARQL queries on the Resource Descrip-
tion Framework (RDF) representation of curated variant data from
UniProtKB/Swiss-Prot is being developed. This will allow users to
perform complex queries to search for variants occurring at known
functionally relevant sites (query examples are provided in the Sup-
porting Information).
Because of their reliability, UniProtKB/Swiss-Prot annotations
have also been used to develop prediction methods to estimate the
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Figure 2. Excerpt from UniProtKB/Swiss-Prot entry Q5HYA8 representing human Meckelin (TMEM67). The “Sequence annotation (Features)”
section describes the sequence and sequence variants at the single residue level. Note the presence of three types of variants: a neutral
polymorphism at position 261, disease variants associated with ciliopathies MKS3, COACHS, and NPHP11, and VUS at positions 245 and 296.
Note that disease-linked variant p.Asn242Thr affects a predicted N-glycosylation site (see subsection “Amino acid modifications”). Disease-linked
variant p.Gln376Pro perturbs protein subcellular location.
pathogenicity of missense variants [Thusberg et al., 2011; Capriotti
et al., 2013; Shihab et al., 2013; Yates and Sternberg, 2013].
Involvement in Disease
A good example to highlight the richness of UniProtKB/Swiss-
Prot annotations is provided by proteins associated with ciliopathies,
a group of diseases caused by abnormal cilia formation or function
[Yuan and Sun, 2013]. Ciliopathies cover a large spectrum of of-
ten overlapping phenotypes [Waters and Beales, 2011]. The clinical
overlap between different ciliopathies and their variable penetrance
and expressivity are due to multilocus allelism with clinical outcome
depending on the global mutational load in genes involved in cilia
biology [Beales et al., 2003; Khanna et al., 2009; Davis et al., 2011].
Successful identification of gene mutations involved in ciliopathies
has shown the role of disease-causing and disease-modifying genes,
as well as gene–gene interactions, emphasizing the complexity of
biological and pathological events.
For example, mutations in the TMEM67 gene (UniProtKB/Swiss-
Prot accession Q5HYA8) have been shown to cause Meckel syn-
drome 3, Joubert syndrome 6, COACH syndrome, and nephronoph-
thisis 11. This information is reported in the “Note” of the “In-
volvement in disease” subsection using the standardized expression
“The disease is caused by mutations affecting the gene represented
in this entry”. However, TMEM67 has been also associated with
Bardet–Biedl syndrome, where it probably acts as a modifier. This
information is annotated in the “Note” as “The gene represented in
this entry may act as a disease modifier” (Fig. 4). The note may also
contain additional interesting information written in free text, such
as explanations of the pathological mechanism at molecular level.
For example, TRIM32 (UniProtKB/Swiss-Prot accession Q13049)
has been shown to cause Bardet–Biedl syndrome 11 (BBS11). The
role of TRIM32 in BBS11 pathogenesis is not obvious, since it is not
directly involved in cilia function, assembly, or maintenance. It is an
E3 ubiquitin ligase that may act by degrading BBS2, a component
of a large complex involved in ciliary membrane biogenesis [Zhang
et al., 2012]. Although it is a mere hypothesis for the time being,
it gives a hint about the molecular mechanism that may underlie
BBS11 pathogenesis. As such, it is reported in the second part of the
note.
Disease Nomenclature
When a disease is reported in the OMIM database, the OMIM
disease name and acronym are imported into the UniProtKB doc-
umentation and used for annotation. This ensures consistency
between both databases. This nomenclature may sometimes dif-
fer from that found in the medical literature. For example, the
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Figure 3. UniProtKB/Swiss-Prot page for human Meckelin (TMEM67) variant p.Asn242Thr.
ciliopathy currently named “Joubert syndrome” in OMIM has
also been called “cerebello-oculo-renal syndrome”, “cerebelloocu-
lorenal syndrome”, “cerebelloparenchymal disorder”, or “Joubert–
Boltshauser syndrome” in various publications. Although in
UniProtKB/Swiss-Prot entries, we only indicate the current name
“Joubert syndrome” as proposed by the OMIM database, we provide
an exhaustive list of disease synonyms in the humdisease.txt file (see
below). Diseases that are not reported in OMIM are named by the
UniProt curator staff on the basis of published reports.
Retrieving Disease-Associated Proteins from
UniProtKB/Swiss-Prot
A convenient way to retrieve proteins of interest from UniProtKB
is to use appropriate keywords. In UniProtKB/Swiss-Prot, most key-
words are attributed in the course of manual annotation procedure.
They provide a summary of the entry content and can be used to
generate indexes of protein entries based on functional, structural,
or other categories such as “Cellular component,” “Coding sequence
diversity,” and “Disease.” The category “Disease” contains over 150
keywords that are assigned to proteins involved in a disease. In gen-
eral, UniProtKB/Swiss-Prot curators create new medical keywords
when at least two proteins are involved in a specific disorder. Pro-
teins that have been shown in the medical research literature to be
associated with diseases characterized by either abnormal forma-
tion or function of cilia can be retrieved using the keyword “Cil-
iopathy”. The term “Ciliopathy” covers a wide variety of syndromes
that can be associated with more than one defective protein. To
allow targeted searches, more specific keywords have been created
for defined types of ciliopathies, such as “Bardet–Biedl syndrome”,
“Joubert syndrome”, and “Meckel syndrome”. Some keywords are
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Figure 4. Excerpt from the “General annotation (Comments)” section in Q5HYA8, containing functional annotations based on publications.
TMEM67 mutations are involved in several ciliopathies, including Meckel syndrome 3 (MKS3), Joubert syndrome 6 (JBTS6), Bardet–Biedl syndrome
(BBS), COACH syndrome (COACHS), and nephronophthisis 11 (NPHP11). The precise type of association with the disease, i.e. confirmed or probable
pathological role, susceptibility to disease or disease modification, is indicated in the “Note” using a controlled vocabulary.
associated with sequence features. For instance, proteins for which
at least one disease-associated variant is described in “Sequence an-
notation (Features)”, “Natural variant”, can be retrieved using the
keyword “Disease mutation”. The annotation of neutral variants
or VUS into “Sequence annotation (Features)”, “Natural variant”,
drives the addition of the keyword “Polymorphism”. UniProtKB
keywords are stored in a controlled vocabulary list, available online
in the UniProtKB documentation (keywlist.txt file).
On the Importance of Linking Disease
Descriptions to Protein Functional Annotations
Most genes identified so far as ciliopathy-causing factors encode
proteins that are themselves components of the cilia or that are
involved in cilium biogenesis, maintenance, and function. Informa-
tion on the physiological protein function, its subcellular location,
tissue expression, interaction with other proteins, enzymatic activ-
ity, etc., are stored in “General annotation (Comments)” (Fig. 4).
These annotations are classified in specialized subsections, some
written in free text (“Function”, “Tissue specificity”, etc.) and some
in controlled vocabulary (“Subcellular location”, “Catalytic activ-
ity”, etc.). Most controlled vocabulary subsections can contain a free
text “Note =” that allows to qualify the annotation and provides
additional information.
High-quality, detailed, and structured annotations may con-
tribute to the discovery of gene–disease associations. For example,
when a ciliopathy is mapped to a new locus and a list of genes at
this locus is established, a quick glance at UniProtKB/Swiss-Prot
may help to identify which ones are involved in ciliary biology,
hence should be considered in priority as candidates for further
analysis. This information can be easily found in “General anno-
tation (Comments)”, “Function”, or searching with the keywords
“Cilium”, for a protein found in, or associated with a cilium, or
“Cilium biogenesis/degradation”, for proteins involved in the for-
mation, organization, maintenance, and degradation of the cilium.
Additionally, searches can be performed with GO terms related to
cilia biology. Currently, in UniProtKB/Swiss-Prot, 150 proteins
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have been shown to be associated with cilium, either topologically
or functionally, but have not been associated with any type of cil-
iopathy. These proteins could be considered for analysis in patients
negative for mutations in any known ciliopathy genes. Alternatively,
UniProtKB/Swiss-Prot could be convenient source for the identifi-
cation of interaction partners, or as a central hub to access other
specialized resources, such as IntAct (http://www.ebi.ac.uk/intact/)
or STRING (http://string-db.org/).
UniProtKB Genetic Disease and
Variant-Dedicated Documents
Data on genetic diseases and variants are summarized in and
distributed through the documents given below.
Humdisease.txt
The controlled vocabulary used in UniProtKB/Swiss-Prot for the
description of diseases is available in the file humdisease.txt in our
documentation. This file deals only with diseases reported in the
OMIM database. Diseases reported in UniProtKB/Swiss-Prot that
do not have a counterpart in OMIM are written in free text, there-
fore are not represented in this file. The humdisease.txt file lists,
for each disease, its name, acronym, synonyms, phenotypic descrip-
tion, and MeSH terms, and provides cross-references to the OMIM
database. Disease names and acronyms are assigned according to
the OMIM nomenclature, while synonym come from literature re-
ports. Disease names and acronyms are used in “General annotation
(Comments)”, “Involvement in disease”. Acronyms are used in “Se-
quence annotation (Features)”, “Natural variant”.
Humsavar.txt
In release 2014 03 of March 2014, the total number of SAPs an-
notated in UniProtKB/Swiss-Prot was 68,908 (up-to-date statistics
can be found on UniProtKB website). All are listed in the file hum-
savar.txt. This document also indicates if a SAP has been reported
to be disease-associated (24,439 variants), a neutral polymorphism
(37,904), or a VUS (6,565). The humsavar.txt file has been used as
a reliable training set for the development of computational tools
predicting the damaging effects of missense mutations [Care et al.,
2007; Adzhubei et al., 2010].
Homo_sapiens_variation.txt.gz
Variant annotation in UniProtKB/Swiss-Prot is focused on varia-
tions described in the literature. While high-quality expert curation
is essential to support research, it is a slow process that cannot cope
with the flood of data produced at increasing speed by new sequenc-
ing technologies. As a result, many variation data are missing from
UniProtKB/Swiss-Prot. In order to provide users with a complete
set of human variations, we have released a new extension to the
humsavar.txt variant catalogue, the homo sapiens variation.txt.gz.
This new file contains variants not annotated in UniProtKB/Swiss-
Prot entries. It supplements the set of manually curated human
variants in humsavar.txt with a catalogue of novel SAPs from the
1,000 Genomes Project. These variants have been automatically
mapped to UniProtKB sequences, including isoform sequences,
through Ensembl. In addition to defining the position and the amino
acid change due to each variant, the new file maps each affected
UniProtKB record to the corresponding Ensembl gene, transcript
and protein identifiers, and provides the chromosomal location
with allele change. Where possible, a cross-reference to OMIM is
provided. This file, along with the humsavar.txt file, can be found
in the new dedicated “variants” directory on the UniProt FTP site.








UniProtKB/Swiss-Prot Data Integration with
Other Resources
UniProtKB/Swiss-Prot has always striven to provide a high level
of integration with other databases. The 129 databases that are
currently cross-referenced in UniProtKB include nucleotide se-
quence archives (ENA, DDBJ, and GenBank), as well as databases
dedicated to three-dimensional structures (experimental or pre-
dicted), interactions, and pathways. The “Cross-references” sec-
tion also gives access to medically relevant databases, including
DrugBank (http://www.drugbank.ca/), a resource that combines
detailed drug data with comprehensive drug target, PharmGKB
(https://www.pharmgkb.org/), a resource dealing with the im-
pact of genetic variation on drug response, and Orphanet
(http://www.orpha.net/), a free-access portal for information on
rare diseases and orphan drugs. The latter database provides de-
tailed clinical disease descriptions and terminologies. The full list of
cross-references available from the “Cross-references” section and,
in rare cases, “Sequence annotation (Features)” can be found in the
dbxref.txt file.
A dedicated section called “Web resources” has been created to
store links to locus-specific databases that, dealing with a single
gene/disease, aim to record all gene variants identified worldwide.
From this section, users can access information on variants not
annotated in UniProtKB/Swiss-Prot.
Conclusions
UniProtKB/Swiss-Prot is a freely accessible resource that offers
concise and reliable information on proteins. This includes informa-
tion on genetic, mostly disease-linked, variants at the protein level
and a short description of the associated disease. The variant infor-
mation is displayed in the general context of the whole sequence, side
by side with the annotation of domains, post-translational modi-
fications, and secondary structures. The phenotype resulting from
protein alteration is described along with the physiological pro-
tein function, its subcellular location, tissue expression, etc. The
integration of both physiological and pathological data may allow
formulating new hypotheses on the molecular processes that lead to
disease status.
In order to improve the clarity of disease information and to
facilitate its retrieval from UniProtKB, the format of the subsec-
tion “Involvement in disease” is highly structured and written using
standard phrases and controlled vocabulary. As clinical classifica-
tions and terminologies do not generally focus on genetic disease
nomenclature, the disease naming system in UniProtKB follows
the nomenclature provided by OMIM, a highly comprehensive
knowledgebase of genetic syndromes. OMIM disease names are
also used in the Human Phenotype Ontology (HPO) [Köhler et al.,
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2014], a resource that provides a controlled and structured vocabu-
lary of phenotypic abnormalities encountered in human disorders.
The consistency in disease naming in both UniProtKB/Swiss-Prot
and HPO allows the mapping of UniProtKB sequences to HPO
phenotypic terms.
The disease description found in “Involvement in disease” is a very
concise summary from published observations. A detailed pheno-
typic description would be beyond the scope of a general interest
protein knowledgebase, such as UniProtKB. Users interested by this
kind of information should refer either to bibliographic citations
stored in the entries or to cross-references to specialized databases.
Among them is the Orphanet database, a portal for information on
rare diseases. Rare disorders actually represent the majority of the
diseases annotated in UniProtKB/Swiss-Prot. Orphanet maps these
disorders to the International Classification of Diseases (ICD-10),
SNOMED CT, MeSH, MedDRA, and UMLS [Rath et al., 2012].
In this way, cross-references to Orphanet link UniProtKB protein
sequences to clinical terminologies.
UniProtKB/Swiss-Prot annotation is limited to disease-associated
and/or experimentally characterized variants, mostly missense
changes. The rationale is that UniProtKB is widely used in pro-
teomics experiments as a primary database for protein identifi-
cation. Many search engines used for mass spectrometry peptide
identification take into account UniProtKB protein sequences, as
well as all sequence variations annotated in the “Sequence anno-
tation (Features)” section, including genetic variants. As missense
variants represent a frequent type of variation, they have been the
target of high-priority annotation. In this context, complex variants,
such as those producing a premature stop codon, either directly or
by altering splicing, are not relevant. However, this type of complex
variants can be of crucial importance for geneticists that is why we
are setting up a new format that will allow their representation in
the near future.
In order to be useful to the scientific and medical community, the
UniProtKB/Swiss-Prot SAP collection should be highly integrated
with other resources. To be unambiguously identified, genetic vari-
ants are defined at the genomic DNA level. UniProtKB/Swiss-Prot
is a protein knowledgebase and cataloguing variants at the DNA
level is out of its scope. In order to bridge the gap, we have started
to map UniProtKB/Swiss-Prot SAPs to RefSeq or Locus Reference
Genomic (LRG) sequences [Dalgleish et al., 2010; Macarthur et al.,
2014], and to submit them to central resources, such as dbSNP and
Ensembl. A different approach has been taken for the integration
of UniProtKB/Swiss-Prot variants into the University of Califor-
nia Santa Cruz (UCSC) genome browser. Here, UniProtKB/Swiss-
Prot sequences were first aligned to RefSeq sequences and then
UniProtKB/Swiss-Prot variants were lifted to genome positions with
the pslMap program. This demonstrates that the integration of
UniProtKB/Swiss-Prot data collection to genome browsers is not
only possible, but is already achieved and made publicly available at
the UCSC genome browser.
Expert curation is a time-consuming and expensive process, but
it produces most reliable datasets. Improvement of dataset avail-
ability is a major objective in UniProtKB/Swiss-Prot variant anno-
tation. This should be achieved by increasing integration with other
resources and by facilitating parsing through the introduction of
controlled vocabularies as much as possible.
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